

Press Release

NutrigeneAI Co-Hosts CUHK Symposium on Stem Cell Therapies to Advance Clinical Translation in Regenerative Medicine


December 12, 2025, Hong Kong, China –

NutrigeneAI Biotech Limited, in collaboration with the Biotechnology, Entrepreneurship and Healthcare Management (BEHM) Programme at The Chinese University of Hong Kong (CUHK), successfully co-hosted the Symposium on *Stem Cell Therapies: Roadmap to Clinical Applications* on December 12, 2025, at CUHK.

The symposium convened leading clinicians, academic researchers, and industry professionals to examine translational pathways for stem cell-based therapies. Discussions focused on induced pluripotent stem cell (iPSC) technologies, clinical manufacturing and quality systems, regulatory considerations, and real-world applications in regenerative medicine.



From Scientific Discovery to Clinical Practice



Designed as a cross-sector dialogue platform, the symposium addressed key challenges in translating stem cell research from laboratory innovation to clinical implementation. Topics spanned unmet clinical needs in cardiovascular and ischemic diseases, GMP manufacturing strategies, CMC development, and regulatory pathways for advanced therapy medicinal products (ATMPs).

NutrigeneAI participated actively in both the scientific exchange and organizational coordination of the event, reflecting the company's commitment to advancing clinically viable regenerative therapies through collaboration across academia, healthcare institutions, and industry.

Distinguished Speakers and Multidisciplinary Perspectives



The symposium featured a distinguished panel of speakers from CUHK, leading hospitals, innovation platforms, and the biotechnology sector. In programme order, speakers included:

- **Prof. Liwen JIANG**, Pro-Vice-Chancellor (External Affairs), CUHK (Opening Remarks)
- **Prof. Ping Yen Bryan YAN**, Head, Division of Cardiology (Academic Affairs), CUHK (Keynote)
- **Dr. Yang YU**, Assistant President & Director, Party and Government Office of West China Hospital (Lecheng), Sichuan University
- **Prof. Yun LIAO**, Chief Pharmacist, Department of Clinical Pharmacy, Shanghai General Hospital
- **Ms. Elaine CHENG**, Founding Chairman, JSHK Innovative Collaboration Federation (蘇創會)
- **Ms. Carol Y. B. LIU**, Associate Director, Startup Ecosystem (Incu-Bio), HKSTP
- **Mr. Man CHOW**, Assistant Director, Institute for Translational Research, HKSTP
- **Dr. Bill WONG**, Chief Executive Officer, NutrigeneAI Biotech Limited
- **Dr. Stefan BRAAM**, Chief Technical Officer, Cellistic
- **Dr. Gina JIANG**, Managing Director, Hong Kong Institute of Biotechnology
- **Dr. Po-Ying LIN**, Senior Process Development Scientist, Porton Advanced

- **Dr. Peng LI**, Senior Director of CMC, TongEye MedTech

- **Prof. Hung Leung Randolph WONG**, Chief, Division of Cardiothoracic Surgery, Department of Surgery, CUHK

- **Prof. Wing Tak Jack WONG**, Director, BEHM Programme, CUHK (Closing Remarks)

Speakers shared insights grounded in clinical practice, industrial development, manufacturing scalability (CMC/GMP), regulatory readiness, and translational research, fostering multidisciplinary dialogue on accelerating “bench-to-bedside” progress in stem cell-based therapies.

Academic Interaction and Community Engagement



Beyond formal presentations, the symposium emphasized open academic exchange. During tea break sessions, CUHK faculty members, researchers, and students engaged in in-depth discussions, exchanging perspectives on translational research strategies, clinical trial design, and industry collaboration.

The event commenced with a group photo session and the presentation of commemorative gifts to invited speakers, underscoring the collaborative and collegial spirit of the symposium.



NutrigeneAI's Role in Translational Innovation

As a biotechnology company focused on vascular regeneration and ischemic diseases, NutrigeneAI continues to bridge academic research with clinical and industrial development. Through its work on iPSC-derived endothelial cell therapies and cytokine-based regenerative approaches, the company supports platforms that promote safe, scalable, and clinically meaningful innovation.

Co-hosting this symposium reflects NutrigeneAI's broader efforts to foster international academic exchange and contribute to the advancement of regenerative medicine toward real-world clinical impact.

Looking Ahead

By bringing together experts from Hong Kong and beyond, the symposium highlighted the growing momentum of stem cell-based therapies and the importance of cross-disciplinary collaboration. NutrigeneAI looks forward to continued engagement with academic institutions, clinical partners, and industry stakeholders to advance the clinical translation of regenerative medicine.

---Ends---

Media Contact:

Communications Office

NutrigeneAI Biotech Limited

coby.ke@nutrigeneai.com